Mounjaro®
Starting from £179.99/mo
Start journey Learn moreLosing 20 lbs with semaglutide is a realistic goal for many adults — clinical trials of semaglutide for weight management recorded average reductions of around 15% of body weight over 68 weeks at the 2.4mg weekly dose. For someone starting at 190 lbs, 15% is roughly 28 lbs. That said, semaglutide is a prescription-only medicine; a GPhC-registered prescriber has to assess whether it is clinically right for you before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most cited semaglutide trial is STEP 1, published in the New England Journal of Medicine. Adults with obesity or overweight plus a weight-related condition took 2.4mg semaglutide weekly alongside lifestyle support for 68 weeks. On average, participants lost about 15% of their starting weight, versus just over 2% in the placebo group. That difference is large by the standards of any medical intervention.
Put that figure against a 20 lb target and the maths is straightforward: if you weigh 140 lbs, 15% is 21 lbs. If you weigh 180 lbs, it is 27 lbs. For most people in the licensed weight range, 20 lbs sits comfortably within what the trial average suggests is achievable. Some participants lost considerably more; others less. Biology varies, and a trial average is not a personal promise.
It is also worth knowing the trial was 68 weeks, just over a year. Significant weight loss typically builds across months, not weeks. The first few months are spent titrating the dose slowly upward to reduce nausea and let your body settle. You can read more about the biology behind this on our page about how semaglutide works to lose weight.
Semaglutide for weight loss follows a careful titration schedule. Treatment begins at 0.25mg weekly and moves through 0.5mg, 1.0mg and 1.7mg before reaching the standard 2.4mg maintenance dose, with roughly a month at each level. The starting dose exists to give your system time to adjust, gastrointestinal side effects like nausea, loose stools and indigestion are most noticeable in the early weeks and tend to settle as you climb toward maintenance.
What this means for a 20 lb goal is that patience is built into the process. Most of the weight loss documented in STEP 1 happened once participants were established on higher doses, not in the first month. Expecting dramatic change at 0.25mg is a recipe for frustration; expecting steady change over the full course is more realistic.
If you are curious whether the evidence stacks up for your specific situation, our dedicated page on whether semaglutide helps with weight loss covers the clinical picture in more depth, including factors that affect individual response.
In the UK, semaglutide for weight management is licensed under the brand name Wegovy. The NHS medicines page for semaglutide confirms it is indicated for adults with a BMI of 30 or above, or 27 and above where at least one weight-related condition is present, things like high blood pressure, type 2 diabetes, raised cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.
Being within those numbers is a starting point, not a guarantee. A prescriber also looks at your medical history, any medicines you take, and whether there are reasons semaglutide would not be suitable. Pregnancy, breastfeeding, and trying to conceive are conditions where the medicine is not recommended. People under 18 are outside the licensed indication. History of pancreatitis, certain thyroid conditions, or significant kidney problems all need careful prescriber assessment before treatment can proceed.
Our Wegovy treatment page sets out the full eligibility picture, including what the clinical consultation looks at beyond BMI alone.
Semaglutide is a prescription-only medicine. The only legal route to it in the UK is through a prescriber who has reviewed your health, no shortcuts, and no seller offering it without a clinical assessment is operating legitimately. The MHRA has warned repeatedly about counterfeit weight-loss pens sold online; some have contained insulin and caused hospitalisations. You can verify any online pharmacy on the GPhC register before sharing personal or payment information.
At nume, every consultation is read personally by a GPhC-registered Independent Prescriber the same day. If your application is approved before midday on a working day, treatment is dispatched the same day and arrives with DPD the next working day, in a plain, unbranded box with a tracking link on your phone. The pen itself is a pre-filled, once-weekly injection; nothing needs measuring or drawing up, and if you want to understand how supply is packaged you can find out more on our 20 ml semaglutide page. You can explore how weight loss on semaglutide typically progresses to set realistic expectations before you start. For a quick sense of what private treatment costs and what is included, our Wegovy price comparison page gives an honest overview of the UK private market.
If semaglutide sounds like it might be a fit, checking your eligibility takes a few minutes and costs nothing.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.